265 related articles for article (PubMed ID: 28198380)
1. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
[TBL] [Abstract][Full Text] [Related]
2. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
4. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
5. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
6. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE
Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728
[TBL] [Abstract][Full Text] [Related]
8. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
9. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
10. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
[TBL] [Abstract][Full Text] [Related]
11. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
[TBL] [Abstract][Full Text] [Related]
12. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
13. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
[TBL] [Abstract][Full Text] [Related]
14. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
Qasim SL; Sierra L; Shuck R; Kurenbekova L; Patel TD; Rajapakshe K; Wulff J; Nakahata K; Kim HR; Landesman Y; Unger TJ; Coarfa C; Yustein JT
Oncogene; 2021 Feb; 40(6):1176-1190. PubMed ID: 33414491
[TBL] [Abstract][Full Text] [Related]
15. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
Mohammad RM; Li Y; Muqbil I; Aboukameel A; Senapedis W; Baloglu E; Landesman Y; Philip PA; Azmi AS
Small GTPases; 2019 Sep; 10(5):367-377. PubMed ID: 28641032
[TBL] [Abstract][Full Text] [Related]
16. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
18. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells
Jagadish N; Devi S; Gupta N; Suri V; Suri A
Tumour Biol; 2020 Apr; 42(4):1010428320914477. PubMed ID: 32342732
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Mitchell SR; Larkin K; Grieselhuber NR; Lai TH; Cannon M; Orwick S; Sharma P; Asemelash Y; Zhang P; Goettl VM; Beaver L; Mims A; Puduvalli VK; Blachly JS; Lehman A; Harrington B; Henderson S; Breitbach JT; Williams KE; Dong S; Baloglu E; Senapedis W; Kirschner K; Sampath D; Lapalombella R; Byrd JC
Blood Adv; 2019 Feb; 3(3):242-255. PubMed ID: 30692102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]